Macrogenics (MGNX) Gains from Investment Securities (2013)

Macrogenics' (MGNX) quarterly Gains from Investment Securities came in at $554000.0 in Q3 2013, up 1236.42% on a QoQ basis from $41454.0 in Q2 2013.

Macrogenics (MGNX) Gains from Investment Securities (2013) Analysis & Trends

Macrogenics (MGNX) has 1 years of Gains from Investment Securities data on file, last reported at $554000.0 in Q3 2013.

On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $554000.0 in Q3 2013; TTM through Dec 2013 was $626000.0, a N/A change from a year earlier, with the FY2013 full-year figure at $626000.0, up 514.57% from the prior year.
Gains from Investment Securities for Q3 2013 stood at $554000.0, up from $41454.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for MGNX reached as high as $554000.0 in Q3 2013 and fell as low as $30546.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Macrogenics	255.39 Mn	188.87 Mn	-

Download Data